SCHEMBL6177261

SCHEMBL6177261

CN1CCC(Oc2cc(NS(=O)(=O)c3cccc4c(Cl)cccc34)ccc2Cl)C1

nearest known ligand 0.66

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 9/20 0.66
HTR6 P50406 7/20 0.59
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44
WDR5 P61964 1/20 0.43
HTR1A P08908 1/20 0.41
HTR1D P28221 1/20 0.41
HTR1B P28222 1/20 0.41
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41
HTR1F P30939 1/20 0.41
HTR7 P34969 1/20 0.41
SGK1 O00141 1/20 0.41
GHSR Q92847 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6177259 1.00 UTS2R (0.66) UTS2RHTR6ALDH1A1LMNAWDR5
SCHEMBL6672599 0.89 UTS2R (0.66) UTS2RHTR6
SCHEMBL8342125 0.87 UTS2R (0.66) UTS2RHTR6ALDH1A1LMNAHTR2C
SCHEMBL6706961 0.86 UTS2R (0.66) UTS2RHTR6ALDH1A1LMNAHTR1A
SCHEMBL5835483 0.85 UTS2R (0.72) UTS2RHTR6SGK1
SCHEMBL5835487 0.85 UTS2R (0.72) UTS2RHTR6SGK1
SCHEMBL6179408 0.84 UTS2R (0.59) UTS2RHTR6ALDH1A1LMNASGK1
SCHEMBL6750398 0.84 UTS2R (0.59) UTS2RHTR6ALDH1A1LMNASGK1
SCHEMBL5834957 0.84 UTS2R (0.71) UTS2RHTR6ALDH1A1LMNASGK1
SCHEMBL5834952 0.84 UTS2R (0.71) UTS2RHTR6ALDH1A1LMNASGK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1385841-A4 SULFONAMIDES SMITHKLINE BEECHAM CORP (US) 2005-03-02 EP claimed
US-20040142948-A1 Sulfonamides DHANAK DASHYANT (US) 2004-07-22 US claimed
EP-1385841-A1 SULFONAMIDES SmithKline Beecham Corporation (US) 2004-02-04 EP claimed
WO-2002090353-A1 SULFONAMIDES SMITHKLINE BEECHAM CORPORATION (US) 2002-11-14 WO claimed
EP-1385841-A4 SULFONAMIDES SMITHKLINE BEECHAM CORP (US) 2005-03-02 EP disclosed
US-20040142948-A1 Sulfonamides DHANAK DASHYANT (US) 2004-07-22 US disclosed
EP-1385841-A1 SULFONAMIDES SmithKline Beecham Corporation (US) 2004-02-04 EP disclosed
WO-2002090353-A1 SULFONAMIDES SMITHKLINE BEECHAM CORPORATION (US) 2002-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142948-A1 Sulfonamides UTS2R, PRSS2, STS UTS2R 1/4885HTR6 2239/4885ALDH1A1 3733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.